These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1334 related articles for article (PubMed ID: 14681504)

  • 21. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
    Kirby RS; Roehrborn C; Boyle P; Bartsch G; Jardin A; Cary MM; Sweeney M; Grossman EB;
    Urology; 2003 Jan; 61(1):119-26. PubMed ID: 12559281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Can J Urol; 2005 Feb; 12(1):2508-9; author reply 2509-10. PubMed ID: 15777487
    [No Abstract]   [Full Text] [Related]  

  • 25. Benign prostatic hyperplasia: use of drug therapy in primary care.
    Beduschi R; Beduschi MC; Oesterling JE
    Geriatrics; 1998 Mar; 53(3):24-8, 33-4, 37-40. PubMed ID: 9511773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benign prostatic hyperplasia (BPH).
    Harv Mens Health Watch; 2006 Aug; 11(1):3. PubMed ID: 17111474
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
    Fitzpatrick JM; Desgrandchamps F
    BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked].
    MMW Fortschr Med; 2003 Jul; 145(27-28):58-9. PubMed ID: 14587193
    [No Abstract]   [Full Text] [Related]  

  • 32. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.
    Bhardwa J; Goldstraw M; Tzortzis S; Kirby R
    Expert Opin Pharmacother; 2007 Jun; 8(9):1337-44. PubMed ID: 17563267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma].
    Bogdanov AB; Luk'ianov IV; Veliev EI
    Urologiia; 2008; (6):44-9. PubMed ID: 19248599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Roehrborn CG; Siegel RL
    Urology; 1996 Sep; 48(3):406-15. PubMed ID: 8804494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benign prostatic hyperplasia.
    Doherty AP
    Hosp Med; 2003 Feb; 64(2):114. PubMed ID: 12619342
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.